Home Health Startups Niramai: Detecting breast cancer through AI

Niramai: Detecting breast cancer through AI

SHARE
Niramai: Detecting breast cancer through AI
Niramai co-founder Dr Geetha Manjunath and Nidhi Mathur. Photo credit: Niramai

According to the World health organisation, the fatality rate of women dying due to breast cancer is very high in India. One out of every two women die because of breast cancer within 5 years of its diagnosis. However, developed countries like US and China show less fatality rate when it comes to breast cancer because of its early detection. India has acute shortage of these facilities and radiography accompanied with the highly expensive screening cost which is unaffordable for a majority of population in India.

In this context, Niramai, a Bangalore based startup has emerged as an angel in disguise which assists women in diagnosis and early detection of breast cancer by using a combination of techniques like machine learning, artificial intelligence, and cloud-based screening to solve the issue of access and cost of breast cancer screening. Niramai stands for Non-Invasive Risk Assessment and works extensively through machine learning as well as artificial intelligence. It incorporates the use of low-cost device that captures high-resolution thermal images without any radiation. Furthermore, with the application of artificial intelligence on these images, breast cancer is detected. The startup’s patented Thermalytix technology using thermography claims to detect tumors five years earlier than the expensive traditional mammography.

Founded in the year 2016 by two women Geetha Manjunath, a PhD in data mining and the semantic web from the Indian Institute of Science, she has earlier worked with Xerox Research Lab and Nidhi Mathur, an MBA from IIM Bangalore, she has worked at Hewlett-Packard and Xerox as well.

Recently, Niramai acquired a seed funding from Pi Ventures accompanied with participation from Axilor Ventures, 500 Startups, Ankur Capital, and Flipkart co-founder Binny Bansal. The funds will be used in strengthening the startup’s IP profile, expanding operations, and making the cancer screening tool readily available for commercial use.

About sheerin Naz

I am a writer by profession having a degree of MBA in Marketing. I have been working in the field of writing from past 2 years and have been published in 3 anthologies. In addition, I also work as writer and have written on a variety of topics ranging from travel, lifestyle, business, marketing etc.

Visit My Website

Comments